Bimatoprost

CHEMBL1200963 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
415.6 g/mol
LogP
2.8
Phase
4

A prostaglandin analogue used as eye drops to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It works by increasing the drainage of fluid from the eye. It is also used in a topical formulation to stimulate eyelash growth.

الوزن الجزيئي

415,6000 g/mol

LogP

2,80

TPSA

89,80 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

آلية العمل

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O

InChI

InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1

Molecular Formula

C25H37NO4

HBD / HBA

4 / 4

الروابط القابلة للدوران

12

الذرات الثقيلة

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A prostaglandin analogue used as eye drops to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It works by increasing the drainage of fluid from the eye. It is also used in a topical formulation to stimulate eyelash growth.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Bimatoprost is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200963. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5311027. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.